Saturn V Capital Management’s Vir Biotechnology VIR Stock Holding History

Saturn V Capital Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.85M	Buy	+770,643	New	+$7.33M	1.13%	19

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Saturn V Capital Management's VIR Position: Q2 2026 in Review

Saturn V Capital Management opened a new position in Vir Biotechnology (VIR) in Q2 2026: 770,643 shares worth $7.85M. The stake represents 1.13% of the portfolio and ranks #19 among its holdings.

237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Saturn V Capital Management held 770,643 shares of Vir Biotechnology worth $7.85M as of Q2 2026.
Vir Biotechnology was a new Saturn V Capital Management position in Q2 2026.
Vir Biotechnology made up 1.13% of Saturn V Capital Management's portfolio in Q2 2026, its #19 holding.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Saturn V Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.